Table A1.
Differences in Patient Characteristics Between Centers Where the Majority of Patients Were Treated With EP (EP-encouraging centers) and Centers Where EP Was Used in Less Than 10% of Patients (EP-discouraging centers)
| Characteristic | Comparing All Patients |
Near/Far Match Analysis |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EP-Encouraging Center (n = 252) |
EP-Discouraging Center (n = 431) |
Standard Difference | P | EP-Encouraging Center (n = 163) |
EP-Discouraging Center (n = 163) |
Standard Difference | P | |||||
| No. of Patients | % | No. of Patients | % | No. of Patients | % | No. of Patients | % | |||||
| Treatment | 1.83 | < .001 | 1.82 | < .001 | ||||||||
| EP | 173 | 68.7 | 16 | 3.7 | 107 | 65.6 | 3 | 1.8 | ||||
| CP | 79 | 31.3 | 415 | 96.3 | 56 | 34.4 | 160 | 98.2 | ||||
| Treatment era | 0.17 | .0964 | 0 | 1 | ||||||||
| 2001-2004 | 95 | 38.9 | 149 | 61.1 | 61 | 50 | 61 | 50 | ||||
| 2005-2007 | 92 | 40.2 | 137 | 59.8 | 60 | 50 | 60 | 50 | ||||
| 2008-2010 | 65 | 30.9 | 145 | 69.1 | 42 | 50 | 42 | 50 | ||||
| Age, years | 0.31 | < .001 | 0.02 | .7250 | ||||||||
| Mean | 62.1 | 65 | 64.5 | 64.2 | ||||||||
| SD | 8.8 | 8.8 | 8.5 | 7.8 | ||||||||
| Stage IIIB | 140 | 55.6 | 64.9 | 8.8 | 0.06 | .4576 | 89 | 54.6 | 102 | 62.6 | 0.17 | .1438 |
| Histology | 0.28 | .0065 | 0.04 | .0210 | ||||||||
| Adenocarcinoma | 54 | 21.4 | 69 | 16 | 32 | 19.6 | 24 | 14.7 | ||||
| NOS | 92 | 36.5 | 123 | 28.5 | 64 | 39.3 | 46 | 28.2 | ||||
| Other | 1 | 0.4 | 6 | 1.4 | 0 | 0.0 | 2 | 1.2 | ||||
| Squamous | 105 | 41.7 | 233 | 54.1 | 67 | 41.1 | 91 | 55.8 | ||||
| Hemoglobin, g/dL | 0.17 | .0346 | .3293 | |||||||||
| Mean | 12.9 | 12.6 | 12.9 | 12.7 | 0.11 | |||||||
| SD | 1.8 | 1.7 | 1.8 | 1.6 | ||||||||
| eGFR, mL/min | 0.13 | .1094 | .3779 | |||||||||
| Mean | 87.5 | 84.4 | 84.3 | 86.6 | 0.10 | |||||||
| SD | 23.9 | 24.4 | 23.8 | 24.3 | ||||||||
| Albumin, g/dL | 0.25 | .0032 | .0029 | |||||||||
| Mean | 3.7 | 3.5 | 3.8 | 3.6 | 0.33 | |||||||
| SD | 0.6 | 0.6 | 0.5 | 0.6 | ||||||||
| Weight loss, % | 0.12 | .1740 | .7829 | |||||||||
| Mean | 3.5 | 4.2 | 3.9 | 4.1 | 0.03 | |||||||
| SD | 6.5 | 6.7 | 6.2 | 5.7 | ||||||||
| Modified NCI score > 2 | 28 | 11.2 | 66 | 15.3 | 0.12 | .1259 | 21 | 12.9 | 19 | 11.7 | 0.04 | .7357 |
Abbreviations: CP, carboplatin-paclitaxel; eGFR, estimated glomerular filtration rate; EP, etoposide-cisplatin; NCI, National Cancer Institute; NOS, not otherwise specified; SD, standard deviation.